Drugmaker AstraZeneca shifts more production to US amid Trump tariffs
by Julia Kollewe from World news | The Guardian on (#6WYCE)
UK and rest of Europe risk losing out to US and China unless they ramp up spending on new medicines, says CEO Pascal Soriot
AstraZeneca said it was shifting the production of some medicines sold in the United States from Europe to the US, to counter the impact of Donald Trump's trade tariffs.
Speaking as the company reported higher sales and profits for the first quarter, the FTSE 100 pharma company reiterated that the UK, and the rest of Europe, risked losing out to the US and China unless they ramped up spending on new medicines. Pascal Soriot, AstraZeneca's chief executive, warned that well-paid" advanced manufacturing and research jobs could move to the US in the long run.
Continue reading...